Abstract
The cellular content of mitochondria changes dynamically during development and in response to external stimuli, but the underlying mechanisms remain obscure. To systematically identify molecular probes and pathways that control mitochondrial abundance, we developed a high-throughput imaging assay that tracks both the per cell mitochondrial content and the cell size in confluent human umbilical vein endothelial cells. We screened 28,786 small molecules and observed that hundreds of small molecules are capable of increasing or decreasing the cellular content of mitochondria in a manner proportionate to cell size, revealing stereotyped control of these parameters. However, only a handful of compounds dissociate this relationship. We focus on one such compound, BRD6897, and demonstrate through secondary assays that it increases the cellular content of mitochondria as evidenced by fluorescence microscopy, mitochondrial protein content, and respiration, even after rigorous correction for cell size, cell volume, or total protein content. BRD6897 increases uncoupled respiration 1.6-fold in two different, non-dividing cell types. Based on electron microscopy, BRD6897 does not alter the percent of cytoplasmic area occupied by mitochondria, but instead, induces a striking increase in the electron density of existing mitochondria. The mechanism is independent of known transcriptional programs and is likely to be related to a blockade in the turnover of mitochondrial proteins. At present the molecular target of BRD6897 remains to be elucidated, but if identified, could reveal an important additional mechanism that governs mitochondrial biogenesis and turnover.
Introduction
Mitochondria are essential organelles, often described as the "powerhouse of the cell," yet their abundance is far from static. Mitochondrial content shifts dynamically based on energy demands, cell type, and environmental stressors. A fundamental biological question persists: how does a cell regulate its mitochondrial "dosage" relative to its physical size?
Typically, mitochondrial content scales linearly with cell volume—larger cells possess more mitochondria. While the transcriptional pathways driving mitochondrial biogenesis (such as the PGC-1α pathway) are well-documented, the mechanisms that maintain this size-to-content ratio or regulate mitochondrial degradation remain poorly understood. This study aimed to identify chemical probes capable of "uncoupling" this relationship, potentially revealing novel regulatory pathways for cellular metabolism.
Methodology and High-Throughput Screening
To investigate these dynamics, researchers developed a high-throughput, image-based assay using Human Umbilical Vein Endothelial Cells (HUVECs). These cells are particularly well-suited for automated microscopy due to their flat morphology and tendency to grow in a single layer.
The team screened a library of 28,786 small molecules, including known bioactives, natural products, and kinase inhibitors. Cells were treated and then stained with three fluorescent markers: Hoechst (nuclear identification), Phalloidin (cell boundary mapping), and MitoTracker (mitochondrial content measurement). Using CellProfiler software, the researchers automatically quantified mitochondrial intensity and cytoplasmic area for every individual cell.
Validation of the primary screen results involved secondary assays to ensure that increased staining correlated with increased metabolic activity. These included qPCR for mitochondrial DNA (mtDNA), ELISA for protein levels, and Seahorse XF24 oxygen consumption assays to measure actual respiration rates. Finally, electron microscopy (EM) was utilized to observe mitochondrial ultrastructure at the nanometer scale.
Results: Uncoupling Mitochondrial Content from Cell Size
The vast majority of the 28,786 compounds tested followed a "coupling rule": chemicals that increased mitochondrial content also increased cell size. This suggests that mitochondrial expansion and cellular growth are typically governed by the same biological program.
However, a tiny subset of molecules broke this rule. The most significant discovery was BRD6897, a molecule that increased mitochondrial content without an accompanying increase in cell size. Interestingly, BRD6897 did not increase the total number of mitochondria or the total area they occupied within the cell. Instead, EM analysis revealed that existing mitochondria became significantly more "electron-dense," suggesting they were more tightly packed with proteins.
Key findings regarding BRD6897 include:
- Respiration: It increased uncoupled respiration by 1.6-fold in both HUVECs and non-dividing 3T3-L1 preadipocytes.
- Protein vs. DNA: While mitochondrial protein levels (e.g., Cytochrome C) increased, mtDNA copy numbers actually decreased, indicating the effect was not driven by standard transcriptional biogenesis.
- Turnover Kinetics: Pulse-chase labeling experiments confirmed that BRD6897 works by inhibiting the turnover of mitochondrial proteins, slowing their degradation rate and leading to a functional "backup" of respiratory machinery.
Discussion and Limitations
BRD6897 represents a new regulatory lever for mitochondrial density. Unlike traditional boosters that activate DNA to synthesize new parts, BRD6897 enhances capacity by slowing down the recycling process.
A significant limitation of the current study is that the exact molecular target of BRD6897 remains unknown. While the physiological changes are well-documented, the specific protein interaction that triggers this turnover blockade has yet to be identified. Furthermore, BRD6897 exhibited toxicity in actively dividing cells, suggesting its current application is best suited for non-dividing, confluent tissues.
Future research will focus on identifying the molecular target of BRD6897. Such a discovery could provide a new therapeutic window for treating metabolic diseases or addressing age-related mitochondrial decline by modulating protein turnover rather than just biogenesis.
Summary updated